Abstract
The Therapeutic Structural Antibody Database (Thera-SAbDab; http://opig.stats.ox.ac.uk/webapps/therasabdab) tracks all antibody- and nanobody-related therapeutics recognized by the World Health Organisation (WHO), and identifies any corresponding structures in the Structural Antibody Database (SAbDab) with near-exact or exact variable domain sequence matches. Thera-SAbDab is synchronized with SAbDab to update weekly, reflecting new Protein Data Bank entries and the availability of new sequence data published by the WHO. Each therapeutic summary page lists structural coverage (with links to the appropriate SAbDab entries), alignments showing where any near-matches deviate in sequence, and accompanying metadata, such as intended target and investigated conditions. Thera-SAbDab can be queried by therapeutic name, by a combination of metadata, or by variable domain sequence - returning all therapeutics that are within a specified sequence identity over a specified region of the query. The sequences of all therapeutics listed in Thera-SAbDab (461 unique molecules, as of 5 August 2019) are downloadable as a single file with accompanying metadata.
Highlights
Immunotherapeutics derived from B-cell genes are an increasingly successful and significant proportion of the global drugs market, designed to treat a wide range of diseases [1,2,3].Whole monoclonal antibody therapies dominate the industry - drugs that mimic natural antibodies by containing two identical variable domain structures with a particular specificity [3]
The broader class of monoclonal therapies includes Fragment antigen binding (Fab) regions, single-chain Fv regions, and singledomain variable fragments
As of June 2019, bispecific monoclonal antibody (mAb), linked Fabs, linked single-chain Fv (scFv) and linked single-domain variable fragments have all been assessed in clinical trials [7]
Summary
Immunotherapeutics derived from B-cell genes are an increasingly successful and significant proportion of the global drugs market, designed to treat a wide range of diseases [1,2,3].Whole monoclonal antibody (mAb) therapies dominate the industry - drugs that mimic natural antibodies by containing two identical variable domain structures with a particular specificity [3]. Whole monoclonal antibody (mAb) therapies dominate the industry - drugs that mimic natural antibodies by containing two identical variable domain structures with a particular specificity [3]. Most databases supply additional metadata for their therapeutic entries, such as clinical trial status, companies involved in development, target specificity, and alternative names.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
